Literature DB >> 19258401

Genetics of pheochromocytoma and paraganglioma in Spanish patients.

Alberto Cascón1, Guillermo Pita, Nelly Burnichon, Iñigo Landa, Elena López-Jiménez, Cristina Montero-Conde, Susanna Leskelä, Luis Javier Leandro-García, Rocío Letón, Cristina Rodríguez-Antona, José Angel Díaz, Emilio López-Vidriero, Anna González-Neira, Ana Velasco, Xavier Matias-Guiu, Anne-Paule Gimenez-Roqueplo, Mercedes Robledo.   

Abstract

CONTEXT: The presence of familial history in pheochromocytoma/paraganglioma patients, including syndromic antecedents, leads in the majority of cases to a positive genetic testing for mutations in one of the major susceptibility genes described so far. Furthermore, it has been reported that in the absence of familial antecedents, about 11-24% of patients also carry a mutation in one of these related genes. In these cases, other clinical aspects like bilaterality, multiplicity, location of the tumors, or age at onset can help to recognize the underlying genes involved.
OBJECTIVE: The objective of the study was to discuss clinical criteria helpful in the genetic diagnosis, placing special emphasis on apparently sporadic cases.
DESIGN: Two hundred thirty-seven nonrelated probands were analyzed for the major susceptibility genes: VHL, RET, SDHB, SDHC, and SDHD. Genetic characterization included both point mutation analysis and gross deletions in the SDH genes performed by multiplex PCR.
RESULTS: As expected, all syndromic probands were genetically diagnosed with a mutation affecting either RET or VHL. A total of 79.1% (19 of 24) and 18.4% (31 of 168) of patients presenting with either nonsyndromic familial antecedents or apparently sporadic presentation were found to carry a mutation in one of the susceptibility genes. Finally, we found a Spanish founder effect for two mutations: SDHB c.166_170delCCTCA and SDHD c.129G>A.
CONCLUSIONS: Germline mutations are rare in apparently sporadic probands diagnosed after age 40 yr (3.9% in our series) and mainly involve SDHB. Therefore, we recommend prioritizing SDHB genetic testing in patients developing isolated tumors at any age, especially those with extraadrenal location or malignant behavior.

Entities:  

Mesh:

Year:  2009        PMID: 19258401     DOI: 10.1210/jc.2008-2756

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

Review 1.  New roles of carboxypeptidase E in endocrine and neural function and cancer.

Authors:  Niamh X Cawley; William C Wetsel; Saravana R K Murthy; Joshua J Park; Karel Pacak; Y Peng Loh
Journal:  Endocr Rev       Date:  2012-03-07       Impact factor: 19.871

Review 2.  An update on the genetics of pheochromocytoma.

Authors:  D Karasek; U Shah; Z Frysak; C Stratakis; K Pacak
Journal:  J Hum Hypertens       Date:  2012-05-31       Impact factor: 3.012

3.  Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling.

Authors:  Alessandro Cama; Fabio Verginelli; Lavinia Vittoria Lotti; Francesco Napolitano; Annalisa Morgano; Andria D'Orazio; Michele Vacca; Silvia Perconti; Felice Pepe; Federico Romani; Francesca Vitullo; Filippo di Lella; Rosa Visone; Massimo Mannelli; Hartmut P H Neumann; Giancarlo Raiconi; Carlo Paties; Antonio Moschetta; Roberto Tagliaferri; Angelo Veronese; Mario Sanna; Renato Mariani-Costantini
Journal:  Acta Neuropathol       Date:  2013-08-18       Impact factor: 17.088

4.  Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT.

Authors:  Tarun Kumar Jain; Rajender Kumar Basher; Nitin Gupta; Jaya Shukla; Shrawan Kumar Singh; Bhagwant Rai Mittal
Journal:  World J Nucl Med       Date:  2016 Jan-Apr

5.  Functional and in silico assessment of MAX variants of unknown significance.

Authors:  Iñaki Comino-Méndez; Luis J Leandro-García; Guillermo Montoya; Lucía Inglada-Pérez; Aguirre A de Cubas; María Currás-Freixes; Carolyn Tysoe; Louise Izatt; Rocío Letón; Álvaro Gómez-Graña; Veronika Mancikova; María Apellániz-Ruiz; Massimo Mannelli; Francesca Schiavi; Judith Favier; Anne-Paule Gimenez-Roqueplo; Henri J L M Timmers; Giovanna Roncador; Juan F Garcia; Cristina Rodríguez-Antona; Mercedes Robledo; Alberto Cascón
Journal:  J Mol Med (Berl)       Date:  2015-06-14       Impact factor: 4.599

Review 6.  Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.

Authors:  Lauren Fishbein; Katherine L Nathanson
Journal:  Cancer Genet       Date:  2012 Jan-Feb

7.  Cancer genomics and inherited risk.

Authors:  Zsofia K Stadler; Kasmintan A Schrader; Joseph Vijai; Mark E Robson; Kenneth Offit
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

8.  Genetic screening for von Hippel-Lindau gene mutations in non-syndromic pheochromocytoma: low prevalence and false-positives or misdiagnosis indicate a need for caution.

Authors:  G Eisenhofer; C D Vocke; A Elkahloun; T-T Huynh; T Prodanov; J W M Lenders; H J Timmers; J N Benhammou; W M Linehan; K Pacak
Journal:  Horm Metab Res       Date:  2012-03-21       Impact factor: 2.936

Review 9.  Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.

Authors:  Susan Richter; Nan Qin; Karel Pacak; Graeme Eisenhofer
Journal:  Adv Pharmacol       Date:  2013

10.  Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.

Authors:  Esmeralda Castelblanco; Maria Santacana; Joan Valls; Aguirre de Cubas; Alberto Cascón; Mercedes Robledo; Xavier Matias-Guiu
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.